1008 Cytokinetics
BioCentury & Getty Images

Product Development

Next up for Cytokinetics: readout in CV setting that sparked BMS’s $13B MyoKardia takeout

Biotech stays optimistic on omecamtiv even as heart failure data sink shares, shave $10B off Amgen’s value

By stephen hansen, associate editor
Oct 8, 2020 | 10:33 PM GMT
Editor's note: This article has been updated to correct the next milestone for the METEORIC-HF trial. Updated on Oct 9, 2020 at 6:38 PM GMT

Pivotal heart failure data 14 years in the making tripped up Cytokinetics and Amgen Thursday, leaving the former company looking ahead to 1H21 to complete

Read the full 659 word article

How to gain access

Continue reading with a
two-week free trial.